Management of breakthrough pain in patients with cancer

Drugs

Volumn 68, Issue 7, 2008, Pages 913-924

  William, Leeroy ^a   MacLeod, Rod ^b  

^a NORTH SHORE HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer pain, treatment; Fentanyl, therapeutic use; Opioid analgesics, therapeutic use

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CLONAZEPAM; CORTICOSTEROID; DESIPRAMINE; FENTANYL; FENTANYL CITRATE; GABAPENTIN; IBANDRONIC ACID; IMIPRAMINE; LAMOTRIGINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; PAMIDRONIC ACID; PREGABALIN; RADIOISOTOPE; SAMARIUM 153; STRONTIUM 89; SUFENTANIL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZOLEDRONIC ACID;

ALGORITHM; ANALGESIA; BREAKTHROUGH PAIN; CANCER PAIN; CANCER PATIENT; CONFUSION; CONSTIPATION; DROWSINESS; EVIDENCE BASED PRACTICE; FAMILY COUNSELING; HUMAN; MYOCLONUS; NAUSEA; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 43249098839     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868070-00003     Document Type: Review

References (121)

1. 1. CS Cleeland R Gonin AK Hatfield 1994 Pain and its treatment in outpatients with metastatic cancer N Engl J Med 330 9 592 6 7508092 1:STN:280:DyaK2c7jsVWnsw%3D%3D 10.1056/NEJM199403033300902 Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994 Mar 3; 330(9): 592–6
2. 2. MS Hyun JL Lee KH Lee 2003 Pain and its treatment in patients with cancer in Korea Oncology 64 3 237 44 12697964 10.1159/000069314 Hyun MS, Lee JL, Lee KH, et al. Pain and its treatment in patients with cancer in Korea. Oncology 2003; 64(3): 237–44
3. 3. DP Kelsen RK Portenoy HT Thaler 1995 Pain and depression in patients with newly diagnosed pancreas cancer J Clin Oncol 13 3 748 55 7884435 1:STN:280:DyaK2M7ptVGhtA%3D%3D Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995 Mar; 13(3): 748–55
4. 4. F Larue SM Colleau L Brasseur 1995 Multicentre study of cancer pain and its treatment in France BMJ 310 6986 1034 7 7728056 1:STN:280:DyaK2M3ksFaitA%3D%3D 10.1136/bmj.310.6986.1034 Larue F, Colleau SM, Brasseur L, et al. Multicentre study of cancer pain and its treatment in France. BMJ 1995 Apr 22; 310(6986): 1034–7
5. 5. RK Portenoy AB Kornblith G Wong 1994 Pain in ovarian cancer patients: prevalence, characteristics, and associated symptoms Cancer 74 3 907 15 8039118 1:STN:280:DyaK2czhtlGgtA%3D%3D 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-# Portenoy RK, Kornblith AB, Wong G. Pain in ovarian cancer patients: prevalence, characteristics, and associated symptoms. Cancer 1994 Aug 1; 74(3): 907–15
6. 6. RL Daut CS Cleeland 1982 The prevalence and severity of pain in cancer Cancer 50 9 1913 8 7116316 1:STN:280:DyaL3s%2FgtFKltw%3D%3D 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982 Nov 1; 50(9): 1913–8
7. 7. LP Ger ST Ho JJ Wang 1998 The prevalence and severity of cancer pain: a study of newly-diagnosed cancer patients in Taiwan J Pain Symptom Manage 15 5 285 93 9654833 1:STN:280:DyaK1czhvV2jsA%3D%3D 10.1016/S0885-3924(98)00017-7 Ger LP, Ho ST, Wang JJ, et al. The prevalence and severity of cancer pain: a study of newly-diagnosed cancer patients in Taiwan. J Pain Symptom Manage 1998 May; 15(5): 285–93
8. 8. E Vuorinen 1993 Pain as an early symptom in cancer Clin J Pain 9 4 272 8 8118092 1:STN:280:DyaK2c7mt1Olsg%3D%3D 10.1097/00002508-199312000-00009 Vuorinen E. Pain as an early symptom in cancer. Clin J Pain 1993 Dec; 9(4): 272–8
9. 9. FJ Brescia RK Portenoy M Ryan 1992 Pain, opioid use, and survival in hospitalized patients with advanced cancer J Clin Oncol 10 1 149 55 1345797 1:STN:280:DyaK38%2Fpt1SmtA%3D%3D Brescia FJ, Portenoy RK, Ryan M, et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992 Jan; 10(1): 149–55
10. 10. S Donnelly D Walsh 1995 The symptoms of advanced cancer Semin Oncol 22 3 67 72 7537907 1:STN:280:DyaK2M3lvVyitQ%3D%3D Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol 1995 Apr; 22 (2 Suppl. 3): 67–72
11. 11. WK Tay RJ Shaw CR Goh 1994 A survey of symptoms in hospice patients in Singapore Ann Acad Med Singapore 23 2 191 6 8080223 1:STN:280:DyaK2czmtFCgsw%3D%3D Tay WK, Shaw RJ, Goh CR. A survey of symptoms in hospice patients in Singapore. Ann Acad Med Singapore 1994 Mar; 23(2): 191–6
12. 12. YH Yun DS Heo IG Lee 2003 Multicenter study of pain and its management in patients with advanced cancer in Korea J Pain Symptom Manage 25 5 430 7 12727040 10.1016/S0885-3924(03)00103-9 Yun YH, Heo DS, Lee IG, et al. Multicenter study of pain and its management in patients with advanced cancer in Korea. J Pain Symptom Manage 2003 May; 25(5): 430–7
13. 13. RK Portenoy D Payne P Jacobsen 1999 Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 1–2 129 34 10353500 1:STN:280:DyaK1M3nvF2nsg%3D%3D 10.1016/S0304-3959(99)00006-8 Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999 May; 81(1–2): 129–34
14. 14. E Bruera T Schoeller R Wenk 1995 A prospective multicenter assessment of the Edmonton staging system for cancer pain J Pain Symptom Manage 10 5 348 55 7673767 1:STN:280:DyaK2MvgsVSmsw%3D%3D 10.1016/0885-3924(95)00052-Z Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995 Jul; 10(5): 348–55
15. 15. S Mercadante L Radbruch A Caraceni 2002 Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care Cancer 94 3 832 9 11857319 10.1002/cncr.10249 Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002 Feb 1; 94(3): 832–9
16. 16. BV Fortner TA Okon RK Portenoy 2002 A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain J Pain 3 1 38 44 14622852 10.1054/jpai.2002.27136 Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002 Feb; 3(1): 38–44
17. 17. BV Fortner G Demarco G Irving 2003 Description and predictors of direct and indirect costs of pain reported by cancer patients J Pain Symptom Manage 25 1 9 18 12565184 10.1016/S0885-3924(02)00597-3 Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003 Jan; 25(1): 9–18
18. 18. RK Portenoy NA Hagen 1990 Breakthrough pain: definition, prevalence and characteristics Pain 41 3 273 81 1697056 1:STN:280:DyaK3czls1aktw%3D%3D 10.1016/0304-3959(90)90004-W Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990 Jun; 41(3): 273–81
19. 19. PH Coluzzi 1998 Cancer pain management: newer perspectives on opioids and episodic pain Am J Hosp Palliat Care 15 1 13 22 9468974 1:STN:280:DyaK1c7jtVahtA%3D%3D 10.1177/104990919801500105 Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care 1998 Jan–Feb; 15(1): 13–22
20. 20. HJ McQuay AR Jadad 1994 Incident pain Cancer Surv 21 17 24 8564992 1:STN:280:DyaK287lslehtQ%3D%3D McQuay HJ, Jadad AR. Incident pain. Cancer Surv 1994; 21: 17–24
21. 21. F Petzke L Radbruch D Zech 1999 Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic J Pain Symptom Manage 17 6 391 401 10388244 1:STN:280:DyaK1MzhsVaquw%3D%3D 10.1016/S0885-3924(99)00023-8 Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage 1999 Jun; 17(6): 391–401
22. 22. KB Svendsen S Andersen S Arnason 2005 Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms Eur J Pain 9 2 195 206 15737812 10.1016/j.ejpain.2004.06.001 Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005 Apr; 9(2): 195–206
23. 23. G Zeppetella CA O’Doherty S Collins 2000 Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice J Pain Symptom Manage 20 2 87 92 10989246 1:STN:280:DC%2BD3cvktlKnsA%3D%3D 10.1016/S0885-3924(00)00161-5 Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000 Aug; 20(2): 87–92
24. 24. AS Stromgren M Groenvold MA Petersen 2004 Pain characteristics and treatment outcome for advanced cancer patients during the first week of specialized palliative care J Pain Symptom Manage 27 2 104 13 15157034 10.1016/j.jpainsymman.2003.06.011 Stromgren AS, Groenvold M, Petersen MA, et al. Pain characteristics and treatment outcome for advanced cancer patients during the first week of specialized palliative care. J Pain Symptom Manage 2004 Feb; 27(2): 104–13
25. 25. A Caraceni C Martini E Zecca 2004 Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey Palliat Med 18 3 177 83 15198130 10.1191/0269216304pm890oa Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med 2004 Apr; 18(3): 177–83
26. 26. A Caraceni RK Portenoy 1999 An international survey of cancer pain characteristics and syndromes: I ASP task force on Cancer Pain International Association for the Study of Pain. Pain 82 3 263 74 1:STN:280:DyaK1Mvhs1Orsg%3D%3D Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes: I ASP task force on Cancer Pain. International Association for the Study of Pain. Pain 1999 Sep; 82(3): 263–74
27. 27. LC Goudas R Bloch M Gialeli-Goudas 2005 The epidemiology of cancer pain Cancer Invest 23 2 182 90 15813511 10.1081/CNV-50482 Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest 2005; 23(2): 182–90
28. 28. SS Hwang VT Chang B Kasimis 2003 Cancer breakthrough pain characteristics and responses to treatment at a VA medical center Pain 101 1-2 55 64 12507700 10.1016/S0304-3959(02)00293-2 Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003 Jan; 101(1-2): 55–64
29. 29. C Saunders 1964 The symptomatic treatment of incurable disease Prescribers J 4 68 73 Saunders C. The symptomatic treatment of incurable disease. Prescribers J 1964; 4: 68–73
30. 30. C Saunders 1996 A personal therapeutic journey BMJ 313 7072 1599 601 8991003 1:STN:280:DyaK2s7ksFelsw%3D%3D 10.1136/bmj.313.7072.1599 Saunders C. A personal therapeutic journey. BMJ 1996 Dec 21–28; 313(7072): 1599–601
31. 31. G Zeppetella MD Ribeiro 2002 Episodic pain in patients with advanced cancer Am J Hospice Pall Care 19 4 267 76 10.1177/104990910201900412 Zeppetella G, Ribeiro MD. Episodic pain in patients with advanced cancer. Am J Hospice Pall Care 2002; 19(4): 267–76
32. 32. NA Hagen C Stiles C Nekolaichuck 2008 The Alberta breakthrough pain assessment tool for cancer patients: a validation study using a Delphi Process and patient think-aloud interviews J Pain Symptom Manage 35 2 136 52 18178370 10.1016/j.jpainsymman.2007.03.016 Hagen NA, Stiles C, Nekolaichuck C, et al. The Alberta breakthrough pain assessment tool for cancer patients: a validation study using a Delphi Process and patient think-aloud interviews. J Pain Symptom Manage 2008; 35(2): 136–52
33. 33. D Bennett A Burton S Fishman 2005 Consensus panel recommendations for the assessment and management of break-through pain: part 2 management J Clin Pharm Ther 30 6 354 61 Bennett D, Burton A, Fishman S, et al. Consensus panel recommendations for the assessment and management of break-through pain: part 2 management. J Clin Pharm Ther 2005; 30(6): 354–61
34. 34. R Payne 2007 Recognition and diagnosis of breakthrough pain Pain Med 8 1 S3 7 17280600 10.1111/j.1526-4637.2006.00269.x Payne R. Recognition and diagnosis of breakthrough pain. Pain Med 2007 Jan; 8 Suppl. 1: S3–7
35. 35. BH McCarberg 2007 The treatment of breakthrough pain Pain Med 8 1 S8 13 17280601 10.1111/j.1526-4637.2006.00270.x McCarberg BH. The treatment of breakthrough pain. Pain Med 2007 Jan; 8 Suppl. 1: S8–13
36. 36. Carroll D, Moore RA, McQuay HJ, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev 2001; (3): CD003222
37. 37. RK Portenoy 1997 Treatment of temporal variations in chronic can-cer pain Semin Oncol 24 16 S16 7-12 1:STN:280:DyaK1c%2Fis1aquw%3D%3D Portenoy RK. Treatment of temporal variations in chronic can-cer pain. Semin Oncol 1997 Oct; 24 (5 Suppl. 16): S16–7–12
38. 38. S Grond D Zech SA Schug 1991 Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life J Pain Symptom Manage 6 7 411 22 1940485 1:STN:280:DyaK38%2Fktl2htw%3D%3D 10.1016/0885-3924(91)90039-7 Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991 Oct; 6(7): 411–22
39. 39. V Ventafridda M Tamburini A Caraceni 1987 A validation study of the WHO method for cancer pain relief Cancer 59 4 850 6 3802043 1:STN:280:DyaL2s7gt1Ghsw%3D%3D 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1 Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer 1987 Feb 15; 59(4): 850–6
40. 40. Martinez-Zapata MJ, Roque M, Alonso-Coello P, et al. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2006; (3): CD003223
41. 41. MP Davis D Walsh R Lagman 2005 Controversies in pharma-cotherapy of pain management Lancet Oncol 6 9 696 704 16129370 1:CAS:528:DC%2BD2MXpslynsrs%3D 10.1016/S1470-2045(05)70317-X Davis MP, Walsh D, Lagman R, et al. Controversies in pharma-cotherapy of pain management. Lancet Oncol 2005 Sep; 6(9): 696–704
42. 42. S Mercadante A Casuccio A Agnello 1999 Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms J Pain Symptom Manage 17 5 351 6 10355213 1:STN:280:DyaK1M3otlKnsg%3D%3D 10.1016/S0885-3924(98)00141-9 Mercadante S, Casuccio A, Agnello A, et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage 1999; 17(5): 351–6
43. 43. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; (1): CD005180
44. 44. S Mercadante 1997 Malignant bone pain: pathophysiology and treatment Pain 69 1–2 1 18 9060007 1:STN:280:DyaK2s3htlansA%3D%3D 10.1016/S0304-3959(96)03267-8 Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997 Jan; 69(1–2): 1–18
45. 45. I Tannock M Gospodarowicz W Meakin 1989 Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 5 590 7 2709088 1:STN:280:DyaL1M3hsF2msQ%3D%3D Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989 May; 7(5): 590–7
46. 46. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002; (2): CD002068
47. 47. JJ Body I Mancini 2002 Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10 5 399 407 12136223 1:STN:280:DC%2BD38zoslygug%3D%3D 10.1007/s005200100292 Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002 Jul; 10(5): 399–407
48. 48. S Mercadante P Villari P Ferrera 2001 Pamidronate in incident pain due to bone metastases J Pain Symptom Manage 22 2 630 1 11503631 1:STN:280:DC%2BD3MvlvVChtg%3D%3D 10.1016/S0885-3924(01)00322-0 Mercadante S, Villari P, Ferrera P, et al. Pamidronate in incident pain due to bone metastases. J Pain Symptom Manage 2001 Aug; 22(2): 630–1
49. 49. V Hirsh NS Tchekmedyian LS Rosen 2004 Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications Clin Lung Cancer 6 3 170 4 15555218 1:CAS:528:DC%2BD2cXhtFCqur%2FK 10.3816/CLC.2004.n.030 Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004 Nov; 6(3): 170–4
50. 50. A Heidenreich C Ohlmann JJ Body 2004 Ibandronate in metastatic bone pain Semin Oncol 31 10 67 72 15490379 1:CAS:528:DC%2BD2cXhtVSlu7zF 10.1053/j.seminoncol.2004.07.026 Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol 2004 Oct; 31 (5 Suppl. 10): 67–72
51. 51. JS Wu G Monk T Clark 2006 Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study Clin Oncol 18 7 539 44 1:STN:280:DC%2BD28rksFShsQ%3D%3D 10.1016/j.clon.2006.05.003 Wu JS, Monk G, Clark T, et al. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol 2006 Sep; 18(7): 539–44
52. 52. S Nilsson P Strang C Ginman 2005 Palliation of bone pain in prostate cancer using chemotherapy and strontium-89: a randomized phase II study J Pain Symptom Manage 29 4 352 7 15857738 1:CAS:528:DC%2BD2MXlt1Cjurc%3D 10.1016/j.jpainsymman.2004.07.008 Nilsson S, Strang P, Ginman C, et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89: a randomized phase II study. J Pain Symptom Manage 2005 Apr; 29(4): 352–7
53. 53. C Ripamonti E Fagnoni T Campa 2007 Incident pain and analgesic consumption decrease after samarium infusion: a pilot study Support Care Cancer 15 3 339 42 16967302 10.1007/s00520-006-0131-9 Ripamonti C, Fagnoni E, Campa T, et al. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 2007 Mar; 15(3): 339–42
54. 54. AW Burton SK Reddy HN Shah 2005 Percutaneous vertebroplasty: a technique to treat refractory spinal pain in the setting of advanced metastatic cancer A case series. J Pain Symptom Manage 30 1 87 95 10.1016/j.jpainsymman.2004.12.011 Burton AW, Reddy SK, Shah HN, et al. Percutaneous vertebroplasty: a technique to treat refractory spinal pain in the setting of advanced metastatic cancer. A case series. J Pain Symptom Manage 2005 Jul; 30(1): 87–95
55. 55. I Lieberman MK Reinhardt 2003 Vertebroplasty and kyphoplasty for osteolytic vertebral collapse Clin Orthop Relat Res 415 S176 86 14600608 10.1097/01.blo.0000093841.72468.a8 Lieberman I, Reinhardt MK. Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop Relat Res 2003 Oct; 415 Suppl.: S176–86
56. 56. H Knotkova M Pappagallo 2007 Adjuvant analgesics Med Clin North Am 91 1 113 24 17164107 1:CAS:528:DC%2BD2sXpsFGntg%3D%3D 10.1016/j.mcna.2006.10.007 Knotkova H, Pappagallo M. Adjuvant analgesics. Med Clin North Am 2007 Jan; 91(1): 113–24
57. 57. RH Dworkin M Backonja MC Rowbotham 2003 Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations Arch Neural 60 11 1524 34 10.1001/archneur.60.11.1524 Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neural 2003 Nov; 60(11): 1524–34
58. 58. NB Finnerup M Otto HJ McQuay 2005 Algorithm for neuropathic pain treatment: an evidence based proposal Pain 118 3 289 305 16213659 1:STN:280:DC%2BD2MnlvVOqug%3D%3D 10.1016/j.pain.2005.08.013 Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005 Dec 5; 118(3): 289–305
59. 59. I Gilron JM Bailey D Tu 2005 Morphine, gabapentin, or their combination for neuropathic pain N Engl J Med 352 13 1324 34 15800228 1:CAS:528:DC%2BD2MXislCjsbY%3D 10.1056/NEJMoa042580 Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005 Mar 31; 352(13): 1324–34
60. 60. H Hugel JE Eilershaw A Dickman 2003 Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain J Pain Symptom Manage 26 6 1073 4 14654258 10.1016/j.jpainsymman.2003.09.005 Hugel H, Eilershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2003 Dec; 26(6): 1073–4
61. 61. S Mercadante F Lodi M Sapio 1995 Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain J Pain Symptom Manage 10 7 564 8 8537699 1:STN:280:DyaK28%2Fnt1Wgtg%3D%3D 10.1016/0885-3924(95)00102-5 Mercadante S, Lodi F, Sapio M, et al. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995 Oct; 10(7): 564–8
62. 62. K Jackson M Ashby P Martin 2001 ‘Burst’ ketamine for refractory cancer pain: an open-label audit of 39 patients J Pain Symptom Manage 22 4 834 42 11576800 1:STN:280:DC%2BD3MrjtVGisg%3D%3D 10.1016/S0885-3924(01)00340-2 Jackson K, Ashby M, Martin P, et al. ‘Burst’ ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage 2001 Oct; 22(4): 834–42
63. 63. P Good F Tullio K Jackson 2005 Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory (‘triple-agent’) therapy for episodes of acute on chronic pain Intern Med J 35 1 39 44 15667467 1:CAS:528:DC%2BD2MXit1Ors78%3D 10.1111/j.1445-5994.2004.00727.x Good P, Tullio F, Jackson K, et al. Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory (‘triple-agent’) therapy for episodes of acute on chronic pain. Intern Med J 2005 Jan; 35(1): 39–44
64. 64. AS Rice 2001 Cannabinoids and pain Curr Opin Investig Drugs 2 3 399 414 11575713 1:CAS:528:DC%2BD3MXivVKrtr8%3D Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs 2001 Mar; 2(3): 399–414
65. 65. RL Fainsinger K Spachynski J Hanson 1994 Symptom control in terminally ill patients with malignant bowel obstruction (MBO) J Pain Symptom Manage 9 1 12 8 7513332 1:STN:280:DyaK2c3itlWgsA%3D%3D 10.1016/0885-3924(94)90141-4 Fainsinger RL, Spachynski K, Hanson J, et al. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994 Jan; 9(1): 12–8
66. 66. S Mercadante A Casuccio S Mangione 2007 Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review J Pain Symptom Manage 33 2 217 23 17280927 1:CAS:528:DC%2BD2sXjtlelsbs%3D 10.1016/j.jpainsymman.2006.06.014 Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 2007 Feb; 33(2): 217–23
67. 67. JC Eisenach S DuPen M Dubois 1995 Epidural clonidine analgesia for intractable cancer pain: the Epidural Clonidine Study Group Pain 61 3 391 9 7478682 1:STN:280:DyaK28%2FlvV2ktw%3D%3D 10.1016/0304-3959(94)00209-W Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain: the Epidural Clonidine Study Group. Pain 1995 Jun; 61(3): 391–9
68. 68. RL Rauck D Cherry MF Boyer 2003 Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain J Pain 4 8 441 7 14622664 1:CAS:528:DC%2BD3sXotVCiurw%3D 10.1067/S1526-5900(03)00730-2 Rauck RL, Cherry D, Boyer MF, et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 2003 Oct; 4(8): 441–7
69. 69. RW Gilbert JH Kim JB Posner 1978 Epidural spinal cord compression from metastatic tumor: diagnosis and treatment Ann Neurol 3 1 40 51 655653 1:STN:280:DyaE1c7osFKgsA%3D%3D 10.1002/ana.410030107 Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978 Jan; 3(1): 40–51
70. 70. JE Bruckman WD Bloomer 1978 Management of spinal cord compression Semin Oncol 5 2 135 40 675259 1:STN:280:DyaE1c3ivVCltQ%3D%3D Bruckman JE, Bloomer WD. Management of spinal cord compression. Semin Oncol 1978 Jun; 5(2): 135–40
71. 71. G Hanks N Cherny M Fallon 2004 Opioid analgesic therapy D Doyle G Hanks N Cherny Oxford textbook of palliative medicine 3rd Oxford University Press Oxford 316 41 Hanks G, Cherny N, Fallon M. Opioid analgesic therapy. In: Doyle D, Hanks G, Cherny N, et al., editors. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press, 2004: 316–41
72. 72. S Mercadante E Arcuri 2006 Breakthrough pain in cancer patients Pain Clinical Updates 14 1 1 4 Mercadante S, Arcuri E. Breakthrough pain in cancer patients. Pain Clinical Updates 2006; 14(1): 1–4
73. 73. RG Twycross A Wilcock S Charlesworth 2002 Palliative care formulary 2nd Radcliffe Medical Press Oxford Twycross RG, Wilcock A, Charlesworth S, et al. Palliative care formulary. 2nd ed. Oxford: Radcliffe Medical Press, 2002
74. 74. S Mercadante E Bruera 2006 Opioid switching: a systematic and critical review Cancer Treat Rev 32 4 304 15 16624490 1:CAS:528:DC%2BD28Xltlemu78%3D 10.1016/j.ctrv.2006.03.001 Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006 Jun; 32(4): 304–15
75. 75. SM Fishman B Wilsey G Mahajan 2002 Methadone reincarnated: novel clinical applications with related concerns Pain Med 3 4 339 48 15099239 10.1046/j.1526-4637.2002.02047.x Fishman SM, Wilsey B, Mahajan G, et al. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002 Dec; 3(4): 339–48
76. 76. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2004; (2): CD003971
77. 77. S Mercadante P Villari P Ferrera 2004 Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose J Pain Symptom Manage 27 4 352 9 15050663 1:CAS:528:DC%2BD2cXktVOqsr8%3D 10.1016/j.jpainsymman.2003.09.006 Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004 Apr; 27(4): 352–9
78. 78. PE Macintyre 2001 Safety and efficacy of patient-controlled analgesia Br J Anaesth 87 36 46 11460812 1:CAS:528:DC%2BD3MXls1Ohtro%3D 10.1093/bja/87.1.36 Macintyre PE. Safety and efficacy of patient-controlled analgesia. Br J Anaesth 2001; 87: 36–46
79. 79. GW Hanks F Conno N Cherny 2001 Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 5 587 93 11237376 1:CAS:528:DC%2BD3MXisVerur8%3D 10.1054/bjoc.2001.1680 Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 Mar 2; 84(5): 587–93
80. 80. O Dale R Hjortkjaer ED Kharasch 2002 Nasal administration of opioids for pain management in adults Acta Anaesthesiol Scand 46 7 759 70 12139528 1:STN:280:DC%2BD38vktFSlug%3D%3D 10.1034/j.1399-6576.2002.460702.x Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002 Aug; 46(7): 759–70
81. 81. D Fitzgibbon D Morgan D Dockter 2003 Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients Pain 106 3 309 15 14659513 1:CAS:528:DC%2BD3sXptlyjsrc%3D 10.1016/S0304-3959(03)00318-X Fitzgibbon D, Morgan D, Dockter D, et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 2003 Dec; 106(3): 309–15
82. 82. K Fisher C Stiles NA Hagen 2004 Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study J Pain Symptom Manage 28 6 619 25 15589088 1:CAS:528:DC%2BD2MXpslKhug%3D%3D 10.1016/j.jpainsymman.2004.03.003 Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2004 Dec; 28(6): 619–25
83. 83. G Zeppetella 2000 Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain Palliat Med 14 1 57 8 10717724 1:STN:280:DC%2BD3c7ot1WrtQ%3D%3D 10.1191/026921600668793500 Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000 Jan; 14(1): 57–8
84. 84. HW Striebel J Pommerening A Rieger 1993 Intranasal fentanyl titration for postoperative pain management in an unselected population Anaesthesia 48 9 753 7 8214490 1:STN:280:DyaK2c%2FislyhtQ%3D%3D 10.1111/j.1365-2044.1993.tb07583.x Striebel HW, Pommerening J, Rieger A. Intranasal fentanyl titration for postoperative pain management in an unselected population. Anaesthesia 1993 Sep; 48(9): 753–7
85. 85. AM Trescot MV Boswell SL Atluri 2006 Opioid guidelines in the management of chronic non-cancer pain Pain Physician 9 1 1 39 16700278 Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006 Jan; 9(1): 1–39
86. 86. JT Farrar J Cleary R Rauck 1998 Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 8 611 6 9554444 1:CAS:528:DyaK1cXivFGisbg%3D 10.1093/jnci/90.8.611 Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998 Apr 15; 90(8): 611–6
87. 87. JM Christie M Simmonds R Patt 1998 Dose-titration, multi-center study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain J Clin Oncol 16 10 3238 45 9779697 1:CAS:528:DyaK1cXmvFGrtLo%3D Christie JM, Simmonds M, Patt R, et al. Dose-titration, multi-center study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998 Oct; 16(10): 3238–45
88. 88. PG Fine M Marcus AJ Boer De 1991 An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain Pain 45 2 149 53 1876422 1:STN:280:DyaK3Mzktleitw%3D%3D 10.1016/0304-3959(91)90181-V Fine PG, Marcus M, De Boer AJ, et al. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991 May; 45(2): 149–53
89. 89. R Schwagmeier N Boerger W Meissner 1995 Pharmacokinetics of intranasal alfentanil J Clin Anesth 7 2 109 13 7598917 1:STN:280:DyaK2Mzit1WmsA%3D%3D 10.1016/0952-8180(94)00023-W Schwagmeier R, Boerger N, Meissner W, et al. Pharmacokinetics of intranasal alfentanil. J Clin Anesth 1995 Mar; 7(2): 109–13
90. 90. G Zeppetella 2001 Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study Palliat Med 15 4 323 8 12054149 1:STN:280:DC%2BD38zht1ChtQ%3D%3D 10.1191/026921601678320304 Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001 Jul; 15(4): 323–8
91. 91. G Zeppetella 2000 An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study J Pain Symptom Manage 20 4 253 8 11027906 1:STN:280:DC%2BD3M%2FkvVWksg%3D%3D 10.1016/S0885-3924(00)00180-9 Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000 Oct; 20(4): 253–8
92. 92. A Duncan 2002 The use of fentanyl and alfentanil sprays for episodic pain [letter] Palliat Med 16 6 550 12465709 10.1191/0269216302pm610xx Duncan A. The use of fentanyl and alfentanil sprays for episodic pain [letter]. Palliat Med 2002 Nov; 16(6): 550
93. 93. JH Helmers H Noorduin A Peer Van 1989 Comparison of intravenous and intranasal sufentanil absorption and sedation Can J Anaesth 36 5 494 7 2529048 1:STN:280:DyaK3c%2FgtlGgtg%3D%3D 10.1007/BF03005373 Helmers JH, Noorduin H, Van Peer A, et al. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 1989 Sep; 36(5): 494–7
94. 94. JB Streisand JR Varvel DR Stanski 1991 Absorption and bioavailability of oral transmucosal fentanyl citrate Anesthesiology 75 2 223 9 1859010 1:STN:280:DyaK3MzhsV2huw%3D%3D 10.1097/00000542-199108000-00009 Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991 Aug; 75(2): 223–9
95. 95. K Jackson M Ashby J Keech 2002 Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain J Pain Symptom Manage 23 6 450 2 12067765 10.1016/S0885-3924(02)00406-2 Jackson K, Ashby M, Keech J. Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain. J Pain Symptom Manage 2002 Jun; 23(6): 450–2
96. 96. PH Coluzzi L Schwartzberg JD Conroy 2001 Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain 91 1–2 123 30 11240084 1:CAS:528:DC%2BD3MXhs1eiu70%3D 10.1016/S0304-3959(00)00427-9 Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001 Mar; 91(1–2): 123–30
97. 97. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006; (1): CD004311
98. 98. SK Blick AJ Wagstaff 2006 Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer Drugs 66 18 2387 93 17181383 1:CAS:528:DC%2BD2sXhs1aktbw%3D 10.2165/00003495-200666180-00013 Blick SK, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006; 66(18): 2387–93; discussion 94-5
99. 99. B Lennernas T Hedner M Holmberg 2005 Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain Br J Clin Pharmacol 59 2 249 53 15676050 1:CAS:528:DC%2BD2MXitFOgsbo%3D 10.1111/j.1365-2125.2004.02264.x Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005 Feb; 59(2): 249–53
100. 100. M Darwish K Tempero M Kirby 2005 Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers Clin Pharmacokinet 44 12 1279 86 16372825 1:CAS:528:DC%2BD28XitFOls7o%3D 10.2165/00003088-200544120-00006 Darwish M, Tempero K, Kirby M, et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005; 44(12): 1279–86
101. 101. M Darwish M Kirby P Robertson 2006 Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics Clin Pharmacokinet 45 8 843 50 16884321 1:CAS:528:DC%2BD28XpvFaqsb0%3D 10.2165/00003088-200645080-00006 Darwish M, Kirby M, Robertson P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 2006; 45(8): 843–50
102. 102. M Darwish M Kirby P Robertson 2006 Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers Clin Ther 28 5 707 14 16861092 1:CAS:528:DC%2BD28Xms1Sisbo%3D 10.1016/j.clinthera.2006.05.015 Darwish M, Kirby M, Robertson P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther 2006 May; 28(5): 707–14
103. 103. RK Portenoy D Taylor J Messina 2006 A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer Clin J Pain 22 9 805 11 17057563 10.1097/01.ajp.0000210932.27945.4a Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006 Nov–Dec;22(9):805–11
104. 104. DJ Dudgeon E Bruera B Gagnon 2007 A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients J Pain Symptom Manage 33 4 365 71 17397698 1:CAS:528:DC%2BD2sXltFOju7Y%3D 10.1016/j.jpainsymman.2006.09.017 Dudgeon DJ, Bruera E, Gagnon B, et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage 2007 Apr; 33(4): 365–71
105. 105. NA Hagen K Fisher C Stiles 2007 Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study J Palliat Med 10 2 331 7 17472503 10.1089/jpm.2006.0163 Hagen NA, Fisher K, Stiles C. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med 2007; 10(2): 331–7
106. 106. DB Carr LC Goudas WT Denman 2004 Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study Pain 108 1–2 17 27 15109503 1:CAS:528:DC%2BD2cXhsVKhtL4%3D 10.1016/j.pain.2003.07.001 Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004 Mar; 108(1–2): 17–27
107. 107. S Mercadante E Arcuri W Tirelli 2000 Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study J Pain Symptom Manage 20 4 246 52 11027905 1:STN:280:DC%2BD3M%2FkvVWluw%3D%3D 10.1016/S0885-3924(00)00194-9 Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20(4): 246–52
108. 108. R Woodruff 2004 Palliative medicine 4th Oxford University Press Oxford Woodruff R. Palliative medicine. 4th ed. Oxford: Oxford University Press, 2004
109. 109. D Walsh 2000 Pharmacological management of cancer pain Semin Oncol 27 1 45 63 10697021 Walsh D. Pharmacological management of cancer pain. Semin Oncol 2000 Feb; 27(1): 45–63
110. 110. T Meuser C Pietruck L Radbruch 2001 Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology Pain 93 3 247 57 11514084 1:STN:280:DC%2BD3MvmvFyjsw%3D%3D 10.1016/S0304-3959(01)00324-4 Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001 Sep; 93(3): 247–57
111. 111. MS Cepeda JT Farrar M Baumgarten 2003 Side effects of opioids during short-term administration: effect of age, gender, and race Clin Pharmacol Ther 74 2 102 12 12891220 1:CAS:528:DC%2BD3sXlvVCrt78%3D 10.1016/S0009-9236(03)00152-8 Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003 Aug; 74(2): 102–12
112. 112. D Walsh NI Rivera MP Davis 2004 Strategies for pain management: Cleveland Clinic Foundation Guidelines for opioid dosing for cancer pain Support Cancer Ther 1 157 64 18628137 10.3816/SCT.2004.n.007 Walsh D, Rivera NI, Davis MP. Strategies for pain management: Cleveland Clinic Foundation Guidelines for opioid dosing for cancer pain. Support Cancer Ther 2004; 1: 157–64
113. 113. N Cherny C Ripamonti J Pereira 2001 Strategies to manage the adverse effects of oral morphine: an evidence-based report J Clin Oncol 19 9 2542 54 11331334 1:CAS:528:DC%2BD3MXjvVelu78%3D Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001 May 1; 19(9): 2542–54
114. 114. S Mercadante P Villari P Ferrera 2004 Addition of a second opioid may improve opioid response in cancer pain: preliminary data Support Care Cancer 12 11 762 6 15206014 10.1007/s00520-004-0650-1 Mercadante S, Villari P, Ferrera P, et al. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004 Nov; 12(11): 762–6
115. 115. T Morita Y Tei S Inoue 2003 Agitated terminal delirium and association with partial opioid substitution and hydration J Palliat Med 6 4 557 63 14516497 10.1089/109662103768253669 Morita T, Tei Y, Inoue S. Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med 2003 Aug; 6(4): 557–63
116. 116. GR Lauretti GM Oliveira NL Pereira 2003 Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients Br J Cancer 89 11 2027 30 14647133 1:CAS:528:DC%2BD3sXpt1CitLs%3D 10.1038/sj.bjc.6601365 Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003 Dec 1; 89(11): 2027–30
117. 117. M Kloke 2004 Gaps and junctions between clinical experience and theoretical framework in the use of opioids Support Care Cancer 12 11 749 51 15480811 10.1007/s00520-004-0711-5 Kloke M. Gaps and junctions between clinical experience and theoretical framework in the use of opioids. Support Care Cancer 2004 Nov; 12(11): 749–51
118. 118. RH Enting C Mucchiano WH Oldenmenger 2005 The ‘pain pen’ for breakthrough cancer pain: a promising treatment J Pain Symptom Manage 29 2 213 7 15733812 10.1016/j.jpainsymman.2004.05.010 Enting RH, Mucchiano C, Oldenmenger WH, et al. The ‘pain pen’ for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage 2005 Feb; 29(2): 213–7
119. 119. JL Parlow B Milne DA Tod 2005 Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series Palliat Med 19 1 3 8 15690862 10.1191/0269216305pm958oa Parlow JL, Milne B, Tod DA, et al. Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series. Palliat Med 2005 Jan; 19(1): 3–8
120. 120. E Freye JV Levy D Braun 2007 Effervescent morphine results in faster relief of breakthrough pain compared to immediate release morphine sulfate tablet Pain Pract 7 4 324 31 17986159 10.1111/j.1533-2500.2007.00157.x Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough pain compared to immediate release morphine sulfate tablet. Pain Pract 2007; 7(4): 324–31
121. 121. RK Portenoy J Messina F Xie 2007 Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study Curr Med Res Opin 23 1 223 33 17207304 1:CAS:528:DC%2BD2sXos1Cnsbs%3D 10.1185/030079906X162818 Portenoy RK, Messina J, Xie F, et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007 Jan; 23(1): 223–33